Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07911579
PHASE1/PHASE2

A Study of SYH2051 in Combination With Irinotecan Hydrochloride Liposome Injection in Subjects With Advanced Solid Tumors

Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

View on ClinicalTrials.gov

Summary

This is a multicenter, open-label, dose-escalation and dose expansion, and cohort-expansion phase Ib/II clinical study to evaluate the safety and antitumor efficacy of SYH2051 in combination with Irinotecan Hydrochloride Liposome Injection in Patients with Advanced Solid Tumors.

Official title: A Phase Ib/ II Clinical Study to Evaluate the Safety and Efficacy of SYH2051 in Combination With Irinotecan Hydrochloride Liposome in Patients With Advanced Solid Tumors

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

154

Start Date

2026-11-30

Completion Date

2029-12-30

Last Updated

2026-11-03

Healthy Volunteers

No

Interventions

DRUG

SYH2051

SYH2051 is an oral medication taken once daily, with dosage selected according to the dose group.

DRUG

Irinotecan Hydrochloride Liposome.

Irinotecan Hydrochloride Liposome is administered by intravenous infusion every 2 weeks (Q2W)

Locations (1)

Tianjin Medical University Cancer Institute & Hospital

Tianjin, Tianjin Municipality, China